Nucor heads into the summer with analyst conviction running unusually high — and options positioning suggesting the market is less certain.
The Street's bullish turn is the clearest signal this week. JP Morgan raised its target to $282 on June 10, keeping an Overweight rating, just days after Wells Fargo lifted its own target to $292. Barclays initiated coverage at Overweight with a $270 target in late May. That cluster of upward revisions from major names has pushed the consensus recommendation difference to the 99th percentile of the ORTEX universe — a reading that places Nucor among the most uniformly liked names across the entire market. The mean price target of $255 sits almost exactly in line with the current price of $254.32, suggesting analysts broadly view the stock as fairly valued at current levels rather than deeply discounted — though the JP Morgan and Wells Fargo targets imply meaningful upside if the bull case plays out.
Options traders are not sharing that conviction without reservation. The put/call ratio hit 0.80 on June 9, more than two standard deviations above its 20-day average of 0.74 — making it the most defensive options reading of the recent period and close to the 52-week high of 0.91. That shift toward put protection arrived as the stock slipped 1.6% on the week to $254.32, even after recovering 0.4% in Monday's session. The contrast is worth noting: analysts are raising targets while options traders are buying insurance.
Short positioning tells a quieter story. Bears retreated sharply — short interest fell roughly 18% in a single day on June 9 to 1.8% of the free float, continuing a decline that has taken positions down about 15% on the week and 7% over the past month. Borrowing costs are negligible at 0.47%, and availability remains extraordinarily loose. There is effectively no squeeze pressure, no meaningful bearish thesis playing out in the lending market, and no structural demand for borrows. This is a stock where the short community has largely stepped aside.
The institutional picture adds an interesting wrinkle. Berkshire Hathaway trimmed its position by roughly 2.5 million shares as of the March quarter, reducing its stake to around 1.7% of shares outstanding — still a holder, but a smaller one. BlackRock added modestly, lifting its position to 8.4% of shares. Inside the company, a cluster of executive vice presidents sold shares on June 1 and June 3, including EVP John Hollatz, who sold over $2.7 million combined across two transactions. The CFO also registered small sales. The 90-day net position is actually a positive 45,340 shares across all insiders, but the recent pattern skews to selling into the stock's 12% monthly rally.
On fundamentals, Nucor's balance sheet quality stands out. The Piotroski F-score recently hit 8, near the maximum, and EPS momentum over 30 and 90 days ranks in the 70th and 79th percentiles respectively. The PE multiple is running at 16.2x and the EV/EBITDA at 9.4x, both drifting higher over the past month alongside the price rally. The dividend score ranks in the 94th percentile, reflecting Nucor's long track record as a reliable income name in the materials space. Peer STLD shed 0.6% on the week while RS added 2.6%, suggesting the metals complex had a mixed week — with CLF the clear underperformer, down nearly 14%.
The next scheduled earnings event is July 30. With analyst targets freshly raised and options traders hedging, the key question heading into that print is whether Nucor's cost discipline and volume trends justify the renewed confidence — or whether the defensive options activity reflects something the analysts haven't yet fully priced in.
See the live data behind this article on ORTEX.
Open NUE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
